Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update.

Abstract

LettersMarch 2023Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 UpdateLisa M. DeTora, PhD, MS, Trevor Lane, MA, DPhil, Angela Sykes, MA, MPhil, Faith DiBiasi, BSc, MBA, Dikran Toroser, PhD, Leslie Citrome, MD, MPHLisa M. DeTora, PhD, MSHofstra University, Hempstead, New YorkSearch for more papers by this author, Trevor Lane, MA, DPhilCity University of Hong Kong, Hong Kong, ChinaSearch for more papers by this author, Angela Sykes, MA, MPhilPfizer, New York, New YorkSearch for more papers by this author, Faith DiBiasi, BSc, MBAOtsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MarylandSearch for more papers by this author, Dikran Toroser, PhDMerck, Boston, MassachusettsSearch for more papers by this author, Leslie Citrome, MD, MPHNew York Medical College, Valhalla, New YorkSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0490 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We thank our colleagues for their comments. We believe that inclusivity is important at all stages of the research process; however, a high-level, principle-based guideline like GPP cannot account for all the subtleties of increased inclusivity. Of note, inclusivity in research design must be addressed well before the publication process. Inclusivity must be considered at all stages of research and publishing across clinical and other research settings, disease states, countries, regions, and communities. Individual authors, investigators, reviewers, steering committee members, patients, and advocates will have thoughts and opinions. It would have been impossible to do justice to every ... Author, Article, and Disclosure InformationAffiliations: Hofstra University, Hempstead, New YorkCity University of Hong Kong, Hong Kong, ChinaPfizer, New York, New YorkOtsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MarylandMerck, Boston, MassachusettsNew York Medical College, Valhalla, New YorkAcknowledgment: The authors thank their GPP 2022 guideline coauthors for their valuable and timely advice and endorsement of this response.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-1460. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoGood Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Lisa M. DeTora , Dikran Toroser , Angela Sykes , Christine Vanderlinden , Fiona J. Plunkett , Trevor Lane , Eline Hanekamp , Laura Dormer , Faith DiBiasi , Dan Bridges , Lise Baltzer , and Leslie Citrome Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Robert Reinhard Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update Farah Asif Metrics Current IssueMarch 2023Volume 176, Issue 3KeywordsClinical trialsDisclosureResearch ethicsResearch reporting guidelines ePublished: 21 March 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...